1Langenmayer I, Nerl C, Knauf W, et al. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized muhicentre study. Br J Haematol, 1996,94:362-369.
2Manro FR, Zinzani P, Zaja F, et al. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. Haematolozica. 2003. 88 : 1348-1357.
3Leporrier M, Chevret S, Cazin B,et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 2001, 98: 2319 -2325.
4Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003,101:6-14.
